XML 27 R12.htm IDEA: XBRL DOCUMENT
v3.22.4

Restructuring, Strategic Transaction and Integration (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2022
Restructuring and Related Activities [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION Restructuring, strategic transaction and integration expenses were $71.4 million, $18.0 million and $28.4 million in 2022, 2021 and 2020, respectively. Restructuring Restructuring charges were $9.7 million, $(1.8) million and $7.9 million in 2022, 2021 and 2020, respectively, and are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations. In 2022, we incurred restructuring charges primarily related to severance in connection with the January 6, 2022 acquisition of Smiths Medical, see Note 2: Acquisitions. In 2021, we adjusted certain facility restructuring liabilities by $2.0 million, shown in the table below under "Other adjustments," to reflect actual amounts owed which resulted in net restructuring credits of $(1.8) million. In 2020, restructuring charges were primarily related to severance and costs related to office and other facility closures. The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands):
|  | Severance Pay and Benefits |  |  | Retention and Facility Closure Costs |  | Total
Accrued balance, January 1, 2021 |  | $ | 1,858 |  |  |  | $ | 1,563 |  |  | $ | 3,421 |
Charges incurred |  | 140 |  |  |  | — |  |  | 140 |
Payments |  | (969) |  |  |  | — |  |  | (969) |
Currency translation |  | (2) |  |  |  | 31 |  |  | 29 |
Other adjustments(1) |  | (528) |  |  |  | (1,429) |  |  | (1,957) |
Accrued balance, December 31, 2021 |  | $ | 499 |  |  |  | $ | 165 |  |  | $ | 664 |
Acquired restructuring charges |  | 5,796 |  |  |  | 1,740 |  |  | 7,536 |
Charges incurred |  | 9,667 |  |  |  | 58 |  |  | 9,725 |
Payments |  | (11,083) |  |  |  | (268) |  |  | (11,351) |
Currency translation |  | (425) |  |  |  | (188) |  |  | (613) |
Other adjustments |  | (38) |  |  |  | — |  |  | (38) |
Accrued balance, December 31, 2022 |  | $ | 4,416 |  |  |  | $ | 1,507 |  |  | $ | 5,923 |
_______________________________________________ (1) The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed. Strategic Transaction and Integration Expenses We incurred $61.7 million, $19.8 million and $20.5 million in strategic transaction and integration expenses in 2022, 2021 and 2020, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2022 were primarily related to transaction and integration expenses associated with our acquisition of Smiths Medical on January 6, 2022 (see Note 2: Acquisitions) which primarily included legal expenses, bank fees, employee costs and a United Kingdom stamp tax. The strategic transaction and integration expenses during 2021 were related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into a definitive agreement to acquire Smiths Medical. The integration expenses during 2020 were related to the integration of HIS and included expenses for the migration of IT systems at our Austin facility.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI https://asc.fasb.org/topic&trid=2175745 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration